In short
- MDM2 and CDK4 sit next to each other on chromosome 12q13-15. Tumours do not mutate them — they make dozens of extra copies of the whole region. That is what “amplification” means.1
- The same amplification defines several different diagnoses: atypical lipomatous tumour, well-differentiated and dedifferentiated liposarcoma, intimal sarcoma, parosteal osteosarcoma.23
- FISH on the tumour tissue is the reference test. MDM2 and CDK4 immunostaining and p16 support it but do not replace it.45
- It is now a treatment target, not only a diagnostic label: in the phase III SARC041 trial the CDK4/6 inhibitor abemaciclib extended median progression-free survival from 1.5 to 9.7 months in dedifferentiated liposarcoma (HR 0.38).8
- MDM2 inhibitors have so far not converted that biology into a positive randomised trial. The MANTRA phase III was negative.10
- One practical warning: MDM2 amplification has been associated with very fast progression on single-agent checkpoint immunotherapy. This is an observation, not settled science — but it is worth raising before anyone starts PD-1 blockade alone.11
What your report is actually saying
A pathology or molecular report that reads “MDM2 amplified”, “MDM2/CDK4 co-amplification” or “MDM2 FISH positive” is describing a copy-number change, not a spelling mistake in a gene. The tumour cell has taken a stretch of the long arm of chromosome 12 — the region called 12q13-15 — and copied it many times over. The copies usually sit in the nucleus as small extra chromosomes.
That stretch carries more than two genes. Alongside MDM2 and CDK4 it typically contains DDIT3, STAT6, GLI1 and HMGA2, which is why tumours with this amplicon can look surprisingly different from one another under the microscope and why an isolated immunostain can mislead.1
Two of the passengers do most of the damage:
- MDM2 is the cell’s brake on p53, the protein that would normally stop a damaged cell from dividing or push it into cell death. Extra MDM2 means p53 is held down — even though the TP53 gene itself is usually intact. That is the rationale behind MDM2 inhibitors: release the brake and let a normal p53 do its job.
- CDK4 drives the cell cycle forward through the retinoblastoma (Rb) checkpoint. Extra CDK4 means the cell keeps entering division. That is the rationale behind CDK4/6 inhibitors.
Notably, in cardiac sarcomas the tumours that lack MDM2 amplification tend to carry a TP53 mutation or a CDKN2A deletion instead — the same two pathways, disabled a different way.5 The amplicon is one route to a common destination.
How it is tested — and why the method matters
| Method | What it shows | How much weight it carries |
|---|---|---|
| FISH (fluorescence in situ hybridisation) for MDM2, often with CDK4 | Counts actual gene copies in the tumour cells against a chromosome 12 control probe | The reference test. This is the result that decides the diagnosis in most centres.4 |
| Immunohistochemistry for MDM2, CDK4, p16 | Shows whether the proteins are overexpressed | Supportive. p16 overexpression is typical of MDM2/CDK4-amplified tumours, but staining alone can be positive without amplification and negative despite it.35 |
| NGS / comprehensive genomic profiling | Reports copy number for MDM2 and CDK4 alongside everything else | Useful and increasingly common, and the only way to see the rest of the genomic picture. Copy-number calls from small biopsies can be less reliable than FISH. |
If your report mentions MDM2 only by immunostaining and no FISH or sequencing was done, that is a reasonable question to put to your team. It is also one of the most common reasons a second opinion at a sarcoma reference centre changes the diagnosis.
Which tumours carry this amplification
This is the part that surprises most people: the amplification is not specific to one diagnosis. It defines a family of tumours that are treated by different specialists, counted in different registries, and named after the place they happened to grow.
| Diagnosis | How often MDM2/CDK4 amplified | Where it usually arises |
|---|---|---|
| Atypical lipomatous tumour / well-differentiated liposarcoma | Defining feature — essentially all cases | Retroperitoneum, limbs, spermatic cord |
| Dedifferentiated liposarcoma (DDLPS) | Defining feature — nearly all cases6 | Retroperitoneum above all |
| Intimal sarcoma | The characteristic finding; used to separate it from other poorly differentiated sarcomas23 | Pulmonary artery, aorta, heart |
| Parosteal and low-grade central osteosarcoma | Characteristic; used diagnostically | Surface and interior of bone |
| A subset of undifferentiated pleomorphic sarcoma and other solid tumours | Variable minority5 | Anywhere |
For someone with intimal sarcoma, this is not a curiosity. It means the largest body of clinical evidence about drugs aimed at your tumour’s driver was generated in dedifferentiated liposarcoma — a disease with perhaps thirty to forty times as many patients, and therefore thirty to forty times as many trials. Reading across from it has limits, and we say so on that page. But ignoring it makes no sense either.
What it changes about treatment
CDK4/6 inhibitors — the one with randomised evidence
Abemaciclib is an oral CDK4/6 inhibitor already used in breast cancer. In a phase II trial of 30 patients with progressing dedifferentiated liposarcoma, median progression-free survival was 33 weeks and 77% were progression-free at 12 weeks.7 The randomised phase III SARC041 then compared abemaciclib against placebo in 108 patients with advanced dedifferentiated liposarcoma and reported median progression-free survival of 9.7 months versus 1.5 months, hazard ratio 0.38 (90% CI 0.25–0.59, p<0.001). Overall survival was not reached in the abemaciclib arm versus 25.5 months (HR 0.55, p=0.07), with 85% of the placebo group crossing over. The objective response rate was only 9% — the drug mostly holds disease still rather than shrinking it.8
That last point matters for how response is judged. A treatment that stabilises rather than shrinks can look like failure on a CT report that only measures diameters.
MDM2 inhibitors — biologically compelling, clinically unproven
Restoring p53 by blocking MDM2 is an attractive idea and has produced tumour responses in early-phase work.9 It has not yet produced a positive randomised trial in this tumour family: MANTRA, comparing the MDM2 inhibitor milademetan against the standard comparator chemotherapy in dedifferentiated liposarcoma, did not meet its primary endpoint.10 Several other MDM2 inhibitors remain in trials, including in combination with immunotherapy — see trials that enrol by amplification.
Checkpoint immunotherapy — a question to raise first
In a retrospective analysis of 155 patients treated with checkpoint inhibitors, every patient with MDM2 family amplification failed treatment within two months, and several showed markedly accelerated tumour growth compared with the period before immunotherapy.11 The series is small and retrospective, later work has been mixed, and this is not a reason to rule immunotherapy out. It is a reason to ask your oncologist explicitly how they weigh it — particularly for single-agent PD-1 or PD-L1 blockade outside a trial.
Why this makes basket trials relevant to you
Classical oncology trials recruit by diagnosis: a liposarcoma trial for liposarcoma patients. A basket trial recruits by molecular alteration instead — any tumour type, as long as it carries the target. For a disease as rare as intimal sarcoma, that distinction is the difference between a handful of eligible trials worldwide and a genuine list.
Several open studies select patients on CDK4 or CDK6 amplification, or on MDM2 amplification with wild-type p53, without caring which organ the tumour started in. We keep a list, with enrolment status and links to the official registry entry, on trials that enrol on MDM2 or CDK4 amplification.
What to ask your team
- Was MDM2 amplification confirmed by FISH or sequencing, or inferred from immunostaining alone?
- Was CDK4 tested as well, and is the tumour Rb-intact? CDK4/6 inhibitors need a working Rb pathway to do anything.
- Is the p53 status known — wild-type or mutated? Several MDM2-inhibitor trials require wild-type p53.
- Given the amplification, does a CDK4/6 inhibitor have a place in my sequence, and if so where?
- Has my case been discussed at a sarcoma reference centre molecular tumour board, and can my profile be matched against basket trials?
- If immunotherapy is being considered, how does the team weigh the MDM2 hyperprogression signal?
Frequently asked
What does MDM2 amplification mean?
It means the tumour cells carry many extra copies of the MDM2 gene, which sits on chromosome 12q13-15 and is usually amplified together with CDK4. Extra MDM2 suppresses the p53 tumour-suppressor protein even though the TP53 gene itself is typically normal. In lipomatous tumours and in intimal sarcoma the finding is used to make the diagnosis.
Is MDM2 amplification the same as an MDM2 mutation?
No. Amplification means extra copies of a normal gene. A mutation means the gene sequence itself is altered. MDM2 in these tumours is amplified, not mutated, which is why reports describe copy numbers or a FISH ratio rather than a variant.
Which cancers have MDM2 and CDK4 amplification?
Atypical lipomatous tumour and well-differentiated liposarcoma, dedifferentiated liposarcoma, intimal sarcoma, parosteal and low-grade central osteosarcoma, and a minority of other solid tumours including some undifferentiated pleomorphic sarcomas.
What is an MDM2 FISH test?
Fluorescence in situ hybridisation counts copies of the MDM2 gene in tumour cells against a control probe on the same chromosome. It is the reference method for confirming amplification and, in most centres, the result that settles the diagnosis.
Does MDM2 amplification make the prognosis worse?
Not as far as is known within this tumour family. In lipomatous tumours and intimal sarcoma the amplification defines the diagnosis rather than predicting its course. What changes outcome is stage, whether complete surgery was possible, and where the patient was treated.
Is there a treatment that targets MDM2 or CDK4 amplification?
For CDK4, yes: the randomised phase III SARC041 trial showed that the CDK4/6 inhibitor abemaciclib extends progression-free survival in advanced dedifferentiated liposarcoma from 1.5 to 9.7 months. For MDM2, inhibitors exist and are in trials, but the randomised MANTRA study of milademetan did not meet its primary endpoint.
Can I join a trial based on the amplification rather than my diagnosis?
Sometimes, yes. Basket trials select patients by molecular alteration across tumour types. Several open studies enrol on CDK4 or CDK6 amplification, or on MDM2 amplification with wild-type p53. We maintain a current list with registry links.
Sources
- Case study and review of the 12q13-15 amplicon. Dedifferentiated liposarcoma exhibiting myxoid liposarcoma-like morphology with DDIT3 co-amplification and STAT6 nuclear expression. Pathology, Research and Practice 2025. doi:10.1016/j.prp.2025.156086 (via PubMed, PMID 40540926).
- Review. Sarcoma gene signatures — MDM2 amplification in well-differentiated and dedifferentiated liposarcoma as well as in intimal sarcoma. Der Pathologe 2011. doi:10.1007/s00292-010-1393-z (via PubMed, PMID 21287318).
- Case series with immunophenotype and molecular profiling. Intimal sarcoma with MDM2/CDK4 amplification and p16 overexpression. International Journal of Molecular Sciences 2023. doi:10.3390/ijms24087535 (via PubMed, PMID 37108696).
- Systematic review. Primary cardiac intimal sarcoma: multi-layered strategy and core role of amplification/co-amplification and immunostaining. Diagnostics 2024. doi:10.3390/diagnostics14090919 (via PubMed, PMID 38732333).
- Targeted sequencing series (9 cases). Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation in the absence of MDM2 amplification; p16 overexpression was found in the MDM2/CDK4-amplified cases. Human Pathology 2022. doi:10.1016/j.humpath.2022.02.006 (via PubMed, PMID 35181378).
- Review. Dedifferentiated liposarcoma: systemic therapy options — nearly all such tumours carry highly amplified MDM2 and CDK4. Current Treatment Options in Oncology 2020. doi:10.1007/s11864-020-0705-7 (via PubMed, PMID 32026050).
- Phase II trial, 30 patients. Therapy-induced senescence contributes to the efficacy of abemaciclib in patients with dedifferentiated liposarcoma; median progression-free survival 33 weeks, 76.7% progression-free at 12 weeks. Clinical Cancer Research 2023. doi:10.1158/1078-0432.CCR-23-2378 (via PubMed, PMID 37695642).
- SARC041, randomised double-blind phase III, 108 patients (NCT04967521). Abemaciclib versus placebo in advanced dedifferentiated liposarcoma: median progression-free survival 9.7 vs 1.5 months, hazard ratio 0.38 (90% CI 0.25–0.59), p<0.001; overall survival not reached vs 25.5 months, HR 0.55 (95% CI 0.28–1.07), p=0.07. Presented at ASCO 2026. doi:10.1200/JCO.2026.44.17_suppl.LBA2.
- First-in-human phase I, 107 patients. Milademetan, an MDM2 inhibitor, in advanced liposarcoma, solid tumours or lymphomas. Journal of Clinical Oncology 2023. doi:10.1200/JCO.22.01285 (via PubMed, PMID 36669146).
- MANTRA, randomised phase III. Milademetan versus the standard comparator chemotherapy in dedifferentiated liposarcoma — the trial did not meet its primary progression-free survival endpoint. Presented at ESMO 2023. Ann Oncol 2023;34(suppl_2):LBA89.
- Retrospective analysis, 155 patients. Hyperprogressors after immunotherapy: MDM2 family amplification and EGFR alterations correlated with time-to-treatment-failure under 2 months after single-agent PD-1/PD-L1 blockade. Clinical Cancer Research 2017. doi:10.1158/1078-0432.CCR-16-3133 (via PubMed, PMID 28351930).